NDC 60763-482 - GLYCOPYRROLATE
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 60763-482
- Package NDCs from labels
- 60763-482-02
- Manufacturer
- Stason Pharmaceuticals | Stason Pharmaceuticals, Inc. | Contract Pharmacal Corp.
- Effective date
- 2021-12-13
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| GLYCOPYRROLATE TABLETS USP 1 mg and 2 mg Rx only | Stason Pharmaceuticals | Stason Pharmaceuticals, Inc. | Contract Pharmacal Corp. | 2021-12-13 | HUMAN PRESCRIPTION DRUG LABEL |
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 60763-482-02 | 2025-02-17 | C162847 | 48780-1 | f386c64a-19ba-0266-e053-dadaa90a7c1a | GLYCOPYRROLATE TABLETS USP 1 mg and 2 mg Rx only |
| 60763-482-02 | 2023-01-30 | C162847 | 48780-1 | f386c64a-19ba-0266-e053-dadaa90a7c1a | GLYCOPYRROLATE TABLETS USP 1 mg and 2 mg Rx only |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| GLYCOPYRROLATE | GLYCOPYRROLATE | Solco Healthcare US, LLC | 2972f22e-378c-450b-8869-1354a9bd0ffc | 2025-11-30 | Warnings, Adverse reactions | V92SO9WP2I |
| GLYCOPYRROLATE | GLYCOPYRROLATE | Solco Healthcare US, LLC | 3707f06a-6cba-4f5c-86ab-fb95bc2a933c | 2025-11-30 | Warnings, Adverse reactions | V92SO9WP2I |
| Glycopyrrolate | GLYCOPYRROLATE | ProPharma Distribution | 430635e8-7c9e-77f6-e063-6294a90a4c8a | 2025-11-07 | Warnings, Adverse reactions | V92SO9WP2I |
| Glycopyrrolate | GLYCOPYRROLATE | Henry Schein, Inc. | 83602e34-7a8c-4606-b43e-23ab909b6c1a | 2025-11-05 | Warnings, Adverse reactions | V92SO9WP2I |
| Glycopyrrolate | GLYCOPYRROLATE | Henry Schein, Inc. | 74d51ba3-0ca0-4a04-aa87-1c243f885bd8 | 2025-11-05 | Warnings, Adverse reactions | V92SO9WP2I |
| Glycopyrrolate | GLYCOPYRROLATE | Accord Healthcare, Inc., | 871797f0-697a-4a29-a37b-d06219e8f266 | 2025-10-17 | Warnings, Adverse reactions | V92SO9WP2I |
| Glycopyrrolate | GLYCOPYRROLATE | Henry Schein, Inc. | 8b4d1798-c0a7-4661-99cd-1e9a23c16386 | 2025-10-16 | Warnings, Adverse reactions | V92SO9WP2I |
| Glycopyrrolate | GLYCOPYRROLATE | Hikma Pharmaceuticals USA Inc. | 960d2dd0-008d-4ec1-ba2e-9388b28b23e2 | 2025-10-09 | Warnings, Adverse reactions | V92SO9WP2I |
| Glycopyrrolate | GLYCOPYRROLATE | ProPharma Distribution | 3f2b4281-55f3-43e3-e063-6294a90a56ba | 2025-09-18 | Warnings, Adverse reactions | V92SO9WP2I |
| GLYCOPYRROLATE | GLYCOPYRROLATE | ProPharma Distribution | 3edcc39d-0e29-4585-e063-6394a90ad512 | 2025-09-15 | Warnings, Adverse reactions | V92SO9WP2I |
| Glycopyrrolate | GLYCOPYRROLATE | ProPharma Distribution | 3edd6a26-dd0f-2411-e063-6394a90affa2 | 2025-09-15 | Warnings, Adverse reactions | V92SO9WP2I |
| Glycopyrrolate | GLYCOPYRROLATE | Alembic Pharmaceuticals Inc. | 327f8a9e-7730-4f38-a7aa-fbddebddf173 | 2025-08-26 | Warnings, Adverse reactions | V92SO9WP2I |
| Glycopyrrolate | GLYCOPYRROLATE | Precision Dose, Inc. | e58f860b-e955-4d71-a128-93bd3812b08d | 2025-08-08 | Warnings, Adverse reactions | V92SO9WP2I |
| GLYRX-PF | GLYCOPYRROLATE | Exela Pharma Sciences, LLC | 2189f3f5-39dc-4e85-b7c6-9515ded59686 | 2025-07-23 | Warnings, Adverse reactions | V92SO9WP2I |
| GLYCOPYRROLATE | GLYCOPYRROLATE | QUAGEN PHARMACEUTICALS LLC | a456eaea-4cd6-4344-8fc6-6f6a3ce0f2c6 | 2025-06-14 | Warnings, Adverse reactions | V92SO9WP2I |
| GLYCOPYRROLATE | GLYCOPYRROLATE | American Health Packaging | 6404fc8e-d109-4950-9dca-c8a85ad90cf3 | 2025-05-18 | Warnings, Adverse reactions | V92SO9WP2I |
| Glycopyrrolate | GLYCOPYRROLATE | Leading Pharma, LLC | 498bce66-6072-4212-8413-ff9888c58f9c | 2025-04-25 | Warnings, Adverse reactions | V92SO9WP2I |
| Glycopyrrolate | GLYCOPYRROLATE | Chartwell RX, LLC | 89090b34-470c-478c-be49-1d2bc48a28f8 | 2025-04-17 | Warnings, Adverse reactions | V92SO9WP2I |
| GLYCOPYRROLATE | GLYCOPYRROLATE | Aurobindo Pharma Limited | 4b3f8b3e-6fa8-471b-8bee-3dac5e3ea1b8 | 2025-04-17 | Warnings, Adverse reactions | V92SO9WP2I |
| Glycopyrrolate | GLYCOPYRROLATE | AvPAK | bd497783-e2d1-130c-e053-2995a90a7fb9 | 2025-03-04 | Warnings, Adverse reactions | V92SO9WP2I |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.